Literature DB >> 12934784

The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease.

Charlene M Flowers1, Judith A Racoosin, Susan L Lu, Julie G Beitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12934784     DOI： 10.4065/78.6.730

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  9 in total

1.  Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease.

Authors:  Heinz Reichmann; Anja Bilsing; Reinhard Ehret; Wolfgang Greulich; Jörg B Schulz; Andreas Schwartz; Olivier Rascol
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

Review 2.  Pharmacologic resistance in prolactinoma patients.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 3.  Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.

Authors:  Malcolm Steiger; W Jost; F Grandas; G Van Camp
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

4.  Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.

Authors:  D Dupuy; J P Lesbre; P Gérard; M Andrejak; O Godefroy
Journal:  J Neurol       Date:  2008-06-16       Impact factor: 4.849

Review 5.  Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies.

Authors:  F Bogazzi; L Manetti; V Raffaelli; M Lombardi; G Rossi; E Martino
Journal:  J Endocrinol Invest       Date:  2008-12       Impact factor: 4.256

6.  Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals.

Authors:  Florence van Hunsel; Laura Peters; Helga Gardarsdottir; Agnes Kant
Journal:  Drug Saf       Date:  2021-02-19       Impact factor: 5.606

Review 7.  The Heart of the Matter: Cardiac Manifestations of Endocrine Disease.

Authors:  Aditya John Binu; Kripa Elizabeth Cherian; Nitin Kapoor; Sujith Thomas Chacko; Oommen George; Thomas Vizhalil Paul
Journal:  Indian J Endocrinol Metab       Date:  2017 Nov-Dec

8.  Mayo Clinic Proceedings 2004: A view of the present, a peek at the future.

Authors:  William L Lanier
Journal:  Mayo Clin Proc       Date:  2004-01       Impact factor: 7.616

9.  Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.

Authors:  Evzen Růzicka; Hana Línková; Martin Penicka; Olga Ulmanová; Lucie Nováková; Jan Roth
Journal:  J Neurol       Date:  2007-08-24       Impact factor: 6.682
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.